ENVERIC BIOSCIENCES, INC. Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two
ENVERIC BIOSCIENCES, INC. (ENVB) had Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two of $405.38 thousand as of 2016-12-31, per its 10-K/A filed 2017-04-04.
Discontinued › Notes › Debt › Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo · last filed 2017-04-04
- 2016-12-31: Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two $405.38K.
| Period end | Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two |
|---|---|
| 2016-12-31 | $405.38K 10-K/A · filed 2017-04-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |